Crispr
Genomics Primer
Commentary: It’s in your DNA
It is almost impossible to pick up a medical journal today without seeing an article or commentary on gene editing.
VIDEO: Highlights in neovascular AMD from ASRS
SEATTLE — In this video, Aleksandra V. Rachitskaya, MD, FASRS, discusses some of the key highlights in neovascular age-related macular degeneration from the ASRS annual meeting.
CRISPR-edited, donor-derived CAR-T shows early promise for T-cell acute leukemia
Two teenagers with T-cell acute lymphoblastic leukemia achieved complete molecular remission after receiving a donor-based investigational chimeric antigen receptor T-cell therapy, phase 1 study results showed.
CRISPR-based therapy shows promise for reducing hereditary angioedema attacks
LOUISVILLE, Ky. — All patients treated with one infusion of NTLA-2002 gene therapy have remained hereditary angioedema attack-free, according to data presented at American College of Allergy, Asthma & Immunology Annual Scientific Meeting.
CRISPR-based genome editing therapy may help in ATTR amyloidosis with cardiomyopathy
CHICAGO — A novel CRISPR-based in vivo gene editing therapy reduced transthyretin levels in patients with hereditary transthyretin amyloidosis with cardiomyopathy, researchers reported at the American Heart Association Scientific Sessions.
Innovations in DLBCL: Antibody-drug conjugates, bispecific antibodies, CRISPR-edited CAR-T
The advent of novel therapies has propelled, and continues to propel, tremendous progress and innovation in diffuse large B-cell lymphoma.
UCSF researchers hope to cure sickle cell disease through CRISPR gene editing
With the aid of $17 million in grant funding, UCSF Benioff Children’s Hospital Oakland will initiate a 4-year trial evaluating CRISPR/Cas9 gene editing as a potential cure for sickle cell disease.
FDA grants orphan drug designation to CRISPR-edited cell therapy for AML
The FDA granted orphan drug designation to NTLA-5001 for treatment of adults with relapsed or refractory acute myeloid leukemia.
FDA grants RMAT designation to CRISPR-edited CAR-T for advanced B-cell malignancies
The FDA granted regenerative medicine advanced therapy designation to CTX110, a chimeric antigen receptor T-cell therapy in development for treatment of relapsed or refractory B-cell malignancies.